Palisade Bio Inc (PALI)

Oct 11, 2026

Palisade Bio director buys $28,800 in PALI stock By Investing.com - Investing.com Nigeria

Oct 11, 2026

Oct 11, 2026

Form 4 Palisade Bio Inc For: 11 October By Investing.com - Investing.com South Africa

Oct 11, 2026

Oct 11, 2026

Palisade Bio director buys $28,800 in PALI stock By Investing.com - Investing.com South Africa

Oct 11, 2026

Oct 11, 2026

Form 4 Palisade Bio Inc For: 11 October By Investing.com - Investing.com Nigeria

Oct 11, 2026

Oct 11, 2026

Palisade Bio director buys $28,800 in PALI stock By Investing.com - Investing.com Canada

Oct 11, 2026

Oct 10, 2026

Form 4 Palisade Bio Inc For: 10 October By Investing.com - Investing.com Nigeria

Oct 10, 2026

Oct 10, 2026

Form 4 Palisade Bio Inc For: 10 October By Investing.com - Investing.com India

Oct 10, 2026

Oct 08, 2026

Palisade Bio (NasdaqCM:PALI) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 08, 2026

Oct 07, 2026

Form 4 Palisade Bio Inc For: 7 October By Investing.com - Investing.com Nigeria

Oct 07, 2026

Oct 07, 2026

Form 4 Palisade Bio Inc For: 7 October By Investing.com - Investing.com Canada

Oct 07, 2026

Oct 07, 2026

Form 4 Palisade Bio Inc For: 7 October By Investing.com - Investing.com UK

Oct 07, 2026

Oct 07, 2026

Palisade Bio CEO John David Finley Settles 3.2M RSUs, Withholds 1.4M Shares for Taxes on Oct 6, 2026 - Kalkine Media

Oct 07, 2026

Oct 05, 2026

A director buys shares at $1.42 and $1.46 in Palisade Bio (PALI). - stocktitan.net

Oct 05, 2026

Sep 29, 2026

KALA BIO, Inc. (KALA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 29, 2026

Sep 29, 2026

Palisade Bio (Nasdaq:PALI)Stock Analysis - Simply Wall Street

Sep 29, 2026

Sep 28, 2026

Palisade Bio to Present Early PALI-2108 Clinical and Biomarker Data at UEG Week 2026 - Quiver Quantitative

Sep 28, 2026

Sep 28, 2026

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026 - GlobeNewswire Inc.

Sep 28, 2026

Sep 28, 2026

A bowel-disease drug showed a response within a week. Palisade Bio will present the findings in October. - Stock Titan

Sep 28, 2026

May 25, 2021

Palisade Bio, Inc. (PALI) Stock Price, News, Quote & History - Yahoo! Finance Canada

May 25, 2021

Sep 23, 2026

Core AI Holdings Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency - manilatimes.net

Sep 23, 2026

Sep 23, 2026

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance - GlobeNewswire Inc.

Sep 23, 2026

Sep 22, 2026

The FDA cleared Palisade Bio’s Crohn’s trial application. First patient dosing is targeted for early 2027. - Stock Titan

Sep 22, 2026

Sep 09, 2026

Here's Why We're Not Too Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn Situation - simplywall.st

Sep 09, 2026

Sep 08, 2026

Palisade Bio (PALI) Advances 5.26% as Shares Test Key Resistance at $2.31Regression Channel - siam.in

Sep 08, 2026

Sep 03, 2026

Palisade Bio to Participate in Upcoming Investor Conferences - GlobeNewswire

Sep 03, 2026

Sep 03, 2026

Three September healthcare conferences will include Palisade Bio management - Stock Titan

Sep 03, 2026

Aug 21, 2026

Palisade Bio (PALI) CEO reallocates 176K shares in gifts - Stock Titan

Aug 21, 2026

Aug 18, 2026

Palisade Bio Q3 EPS Decreased by Brookline Capital Markets - MarketBeat

Aug 18, 2026

Aug 17, 2026

Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView

Aug 17, 2026

Aug 17, 2026

FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - MarketBeat

Aug 17, 2026

Aug 15, 2026

Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeMFI Overbought - dars.gov.et

Aug 15, 2026

Aug 15, 2026

Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeETF Inflow Streak - vinanet.vn

Aug 15, 2026

Aug 14, 2026

Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan

Aug 14, 2026

Aug 14, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 14, 2026

Aug 13, 2026

Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan

Aug 13, 2026

Aug 13, 2026

HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - MarketBeat

Aug 13, 2026

Aug 12, 2026

Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail

Aug 12, 2026

Aug 11, 2026

Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 11, 2026

Aug 11, 2026

H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 11, 2026

Aug 10, 2026

Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Aug 10, 2026

Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia

Aug 10, 2026

Aug 10, 2026

Palisade Bio clears FDA for Phase 2 UC trial - scanx.trade

Aug 10, 2026

Aug 10, 2026

Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Nigeria

Aug 10, 2026

Aug 10, 2026

Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com

Aug 10, 2026

Aug 10, 2026

Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade

Aug 10, 2026

Aug 10, 2026

Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat

Aug 10, 2026

Aug 10, 2026

Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Canada

Aug 10, 2026

Aug 10, 2026

Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative

Aug 10, 2026

Aug 10, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development - The Manila Times

Aug 10, 2026

Aug 10, 2026

Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com UK

Aug 10, 2026